Pain Therapeutics and King Pharmaceuticals have announced positive results of a Phase III study of Remoxy for patients with chronic participated pain. Remoxy is an abuse-deterrent version of long-acting oxycodone. Remoxy has the benefits of oxycodone but can be prescribed by doctors who want to minimize the risks of abuse, misuse or diversion. With prescription pain drug use on the rise, preventing abuse is a major concern. Pain Therapeutics expects to file an NDA for Remoxy in the second half of 2008. If approved, Remoxy will be the first oxycodone on the market designed to deter abuse.
- see this release for more